Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, sildenafil (Revatio®) cannot be endorsed for use within NHS Wales for the treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. |
||
|
||
Medicine details |
||
| Medicine name | sildenafil citrate (Revatio®) | |
| Formulation | 20 mg film-coated tablet | |
| Reference number | 1051 | |
| Indication | For the treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. |
|
| Company | Pfizer Ltd | |
| BNF chapter | Cardiovascular system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 01/11/2011 | |
| Date of issue | 02/11/2011 | |